Handelsavisen
prelaunch
Companies Healthcare 7808.TWO
78
7808.TWO TPEx Biotechnology & Medical Research

7808.Two

$39,40
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
0,00 %
Op margin
-75,4 %
ROE
-8,0 %
Net margin
-63,1 %
Debt / equity
0,01
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

The company operates in the healthcare diagnostics segment, focusing on biotechnology and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.

Business. The company operates in the healthcare diagnostics segment, focusing on biotechnology and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityHealthcare Diagnostics
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-8,0 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 7808.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 7808.TWO. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company operates in the healthcare diagnostics segment, focusing on biotechnology and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityHealthcare Diagnostics
    AI synthesis
    GENERATED

    The company maintains a strong liquidity position, with a current ratio of 19.7, indicating a high ability to meet short-term obligations. However, the company is currently unprofitable, with a net loss of -97,426,000 TWD and a negative return on equity of -8.02%. These figures suggest that the company is not generating returns for shareholders at this time.

    The company's profitability is below the industry median, as evidenced by the negative operating income of -116,446,000 TWD and a negative return on assets of -7.59%. These metrics indicate that the company is not effectively utilizing its assets to generate profit, which is a concern for investors.

    The company's revenue is not segmented by geographic region or product line in the available data, so it is not possible to assess the geographic or segment concentration of its revenue. This lack of detail limits the ability to evaluate the company's exposure to specific markets or products.

    The company's growth trajectory is uncertain, as the available data does not provide forward-looking revenue projections or historical growth rates. The negative operating cash flow of -57,484,000 TWD and the negative free cash flow of -168,849,000 TWD suggest that the company is not generating sufficient cash from operations to fund its activities.

    The company's risk profile is characterized by low liquidity and dilution risk, with no immediate filing-based liquidity or dilution flags detected. The company's capital structure is supported by a low debt-to-equity ratio of 0.01, indicating that it is primarily financed through equity.

    The company has not disclosed any recent events, such as filings or transcripts, that would provide insight into its current operations or strategic direction. This lack of recent activity may indicate a period of stability or a lack of significant developments.

    Key takeaways
    • The company has a strong liquidity position, as indicated by a high current ratio of 19.7.
    • The company is currently unprofitable, with a net loss of -97,426,000 TWD and a negative return on equity of -8.02%.
    • The company's profitability is below the industry median, with a negative operating income of -116,446,000 TWD and a negative return on assets of -7.59%.
    • The company's growth trajectory is uncertain, as the available data does not provide forward-looking revenue projections or historical growth rates.
    • margin_outlook_rationale: The company's margin outlook is negative due to the current net loss and negative return on equity.
    • rd_outlook_rationale: The company's R&D outlook is uncertain as there is no specific information provided on R&D expenditures or future R&D plans.
    • capex_outlook_rationale: The company's capital expenditure outlook is negative, as indicated by the negative capital expenditure of -83,188,000 TWD.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $39,40
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $1.22B
    Net cash
    $43.8M
    Current ratio
    19.7
    Debt / equity
    0.0
    ROA
    -7.6%
    ROE
    -8.0%
    Cash conversion
    59.0%
    CapEx / revenue
    -53.8%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin-75,4 %Above median
    Net Margin-63,1 %Above median
    ROE-8,0 %Above median
    Capex / Rev-53,8 %Bottom quartile
    D/E0,01Above median
    Cash Conv0,59Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • 7808.TWO Market data — financials · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    7808.TWOCanonical
    TPEx · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage